R. Secrest

发表

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

M. Lebwohl, J. Erickson, A. Menter, 2015, The Lancet.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

J. Erickson, T. Luger, M. Ohtsuki, 2016, The New England journal of medicine.

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis

J. Cauley, P. Delmas, S. Dowsett, 2008, Current medical research and opinion.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

S. Cummings, T. Powles, J. Cauley, 2004, Journal of the National Cancer Institute.

A qualitative study exploring the health-related quality of life and symptomatic experiences of adults and adolescents with ulcerative colitis

T. Symonds, M. Kappelman, S. Curtis, 2019, Journal of patient-reported outcomes.

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women.

V. Jackson, J. S. San Martin, S. Carranza-Lira, 2003, American journal of obstetrics and gynecology.

Hypotensive properties of the protein kinase inhibitor, staurosporine, in normotensive and spontaneously hypertensive rats.

J. Turk, M. Cohen, R. Secrest, 1991, Clinical and experimental hypertension. Part A, Theory and practice.

RESPONSE: Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene

S. Cummings, T. Powles, J. Cauley, 2005 .

Endothelial‐Dependent Relaxation Induced by Leukotrienes C4, D4, and E4 in Isolated Canine Arteries

R. Secrest, B. Chapnick, 1988, Circulation research.

Leukotriene D4 relaxes canine renal and superior mesenteric arteries.

R. Secrest, B. Chapnick, E. J. Olsen, 1985, Circulation research.

Endothelin: differential effects in vascular and nonvascular smooth muscle.

M. Cohen, R. Secrest, Roberta J. Secrest, 1989, Life sciences.

Erratum: Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women (American Journal of Obstetrics and Gynecology (2003) 188 (389-394))

V. Jackson, S. Carranza-Lira, R. Secrest, 2003 .

Role of endothelium in responses of isolated hepatic vessels to vasoactive agents.

A. Lonigro, S. Joshi, R. Secrest, 1991, The Journal of pharmacology and experimental therapeutics.

Characterization of the Contractile 5HT Receptor in the Rat Stomach Fundus

R. Secrest, Marlene L. Cohen, R. Kauffman, 1990 .

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

V. Mirone, R. Secrest, L. Viktrup, 2011, European urology.

Tadalafil Administered Once Daily for Treatment of Lower Urinary Tract Symptoms in Korean men with Benign Prostatic Hyperplasia: Results from a Placebo‐Controlled Pilot Study Using Tamsulosin as an Active Control

S. Kraus, Kwangsung Park, J. J. Kim, 2011, Lower urinary tract symptoms.

Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene.

D. Thiebaud, R. Secrest, 2001, Reproduction, fertility, and development.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

T. Powles, S. Martino, J. Costantino, 2004, The oncologist.

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.

O. Johnell, J. Kanis, D. Black, 2003, Bone.

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

C. Roehrborn, R. Secrest, A. Esler, 2012, The journal of sexual medicine.

Tadalafil administered once daily for treatment of Korean men with lower urinary tract symptoms secondary to benign prostatic hyperplasia : Results from a placebo-controlled pilot study using tamsulosin as an active control Proposed

S. Kraus, Kwangsung Park, J. J. Kim, 2010 .

Comparison of contractions to serotonin, carbamylcholine and prostaglandin F2 alpha in rat stomach fundus.

D. Schoepp, M. Cohen, R. Secrest, 1989, The Journal of pharmacology and experimental therapeutics.

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.

C. Roehrborn, R. Secrest, L. Viktrup, 2013, The journal of sexual medicine.

The Synthesis and Biological Activity of a Highly Selective Adenosine A2a Receptor Agonist.

N. Peet, R. Secrest, P. Weintraub, 2000 .

The synthesis and biological activity of a highly selective adenosine A2a receptor agonist.

N. Peet, R. Secrest, P. Weintraub, 1999, Nucleosides and Nucleotides.